JP5398945B2 - ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体 - Google Patents

ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体 Download PDF

Info

Publication number
JP5398945B2
JP5398945B2 JP2002582991A JP2002582991A JP5398945B2 JP 5398945 B2 JP5398945 B2 JP 5398945B2 JP 2002582991 A JP2002582991 A JP 2002582991A JP 2002582991 A JP2002582991 A JP 2002582991A JP 5398945 B2 JP5398945 B2 JP 5398945B2
Authority
JP
Japan
Prior art keywords
toc
ligand
lys
linker unit
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002582991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514321A (ja
JP2005514321A5 (https=
Inventor
ハンス−ユルゲン・ヴェスター
マルグレット・ショッテリウス
マルクス・シュヴァイガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of JP2005514321A publication Critical patent/JP2005514321A/ja
Publication of JP2005514321A5 publication Critical patent/JP2005514321A5/ja
Application granted granted Critical
Publication of JP5398945B2 publication Critical patent/JP5398945B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2002582991A 2001-04-23 2002-04-23 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体 Expired - Fee Related JP5398945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01201466.8 2001-04-23
EP01201466 2001-04-23
PCT/US2002/012565 WO2002085418A2 (en) 2001-04-23 2002-04-23 Tc and re labeler radioactive glycosylated octreotide derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009228998A Division JP2010001313A (ja) 2001-04-23 2009-09-30 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体

Publications (3)

Publication Number Publication Date
JP2005514321A JP2005514321A (ja) 2005-05-19
JP2005514321A5 JP2005514321A5 (https=) 2006-01-05
JP5398945B2 true JP5398945B2 (ja) 2014-01-29

Family

ID=8180193

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002582991A Expired - Fee Related JP5398945B2 (ja) 2001-04-23 2002-04-23 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
JP2009228998A Withdrawn JP2010001313A (ja) 2001-04-23 2009-09-30 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
JP2013023001A Pending JP2013100349A (ja) 2001-04-23 2013-02-08 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009228998A Withdrawn JP2010001313A (ja) 2001-04-23 2009-09-30 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
JP2013023001A Pending JP2013100349A (ja) 2001-04-23 2013-02-08 ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体

Country Status (11)

Country Link
US (2) US7589061B2 (https=)
EP (1) EP1381396B1 (https=)
JP (3) JP5398945B2 (https=)
AT (1) ATE427125T1 (https=)
AU (1) AU2002254691B8 (https=)
BR (1) BR0209074A (https=)
CA (1) CA2443273C (https=)
CZ (1) CZ20032872A3 (https=)
DE (1) DE60231801D1 (https=)
HU (1) HU228811B1 (https=)
WO (1) WO2002085418A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157086A0 (en) * 2003-07-24 2004-02-08 Guy Patchornik Multivalent ligand complexes
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
CN102253174A (zh) * 2011-04-27 2011-11-23 江苏省原子医学研究所 一种受体显像剂标记的化学动力学研究的方法
AU2012302636B2 (en) * 2011-09-04 2016-09-15 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
BR112014004936A2 (pt) * 2011-09-04 2017-04-04 Glytech Inc polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
PL3152226T3 (pl) * 2014-06-06 2019-10-31 Univ Muenchen Tech Modyfikowane cyklopentapeptydy i ich zastosowania
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CN113747927B (zh) * 2019-02-14 2024-10-18 德国癌症研究中心 包含淀粉酶可切割接头的前列腺特异性膜抗原(psma)配体
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194729C (nl) * 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
JP2544159B2 (ja) 1987-10-07 1996-10-16 ハウス食品株式会社 連続蒸煮装置
MY106120A (en) 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
EP0799050B1 (en) 1994-12-07 2004-08-11 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
JPH10512852A (ja) 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
AU1821397A (en) 1995-12-21 1997-11-07 Scripps Research Institute, The Targeted therapeutic or diagnostic agents and methods of making and using same
DE19654764A1 (de) 1996-12-30 1998-07-02 Boehringer Mannheim Gmbh Verfahren zur Herstellung eines Peptidgemisches
EP1068224B1 (en) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
DE19910419A1 (de) 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)

Also Published As

Publication number Publication date
HUP0303987A3 (en) 2010-03-29
WO2002085418A3 (en) 2003-09-12
US20090324497A1 (en) 2009-12-31
AU2002254691B8 (en) 2008-02-14
DE60231801D1 (de) 2009-05-14
JP2005514321A (ja) 2005-05-19
BR0209074A (pt) 2004-08-10
CZ20032872A3 (cs) 2005-01-12
EP1381396A2 (en) 2004-01-21
US7589061B2 (en) 2009-09-15
US20060165593A1 (en) 2006-07-27
ATE427125T1 (de) 2009-04-15
CA2443273A1 (en) 2002-10-31
EP1381396B1 (en) 2009-04-01
US8575100B2 (en) 2013-11-05
HU228811B1 (hu) 2013-05-28
JP2010001313A (ja) 2010-01-07
CA2443273C (en) 2011-09-27
HUP0303987A2 (hu) 2004-03-01
AU2002254691B2 (en) 2007-06-14
JP2013100349A (ja) 2013-05-23
WO2002085418A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
JP2013100349A (ja) ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
La Bella et al. In vitro and in vivo evaluation of a 99mTc (I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors
Decristoforo et al. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3] octreotide
CA2032499C (en) Polypeptide derivatives
JP3647881B2 (ja) 放射性金属元素結合ペプチドの類似化合物
US7147838B2 (en) Gastrin receptor-avid peptide conjugates
Alves et al. Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M (CO) 3]+ moiety
Alshoukr et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors
US7060247B2 (en) Gastrin receptor-avid peptide conjugates
Barda et al. Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer
Alshoukr et al. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
CA2485339C (en) Radiopharmaceutical formulations
Wester et al. Radiolabeled carbohydrated somatostatin analogs: a review of the current status
AU2002254691A1 (en) Tc and Re labeler radioactive glycosylated octreotide derivatives
Giblin et al. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer
Vaidyanathan et al. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers
EP1385556A1 (en) Gastrin-receptor-avid peptide conjugates
Kankanamalage et al. p-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the 186Re/99mTc-tricarbonyl core: Radiochemistry with model complexes and a GRPR-targeting peptide
Kothari et al. 99mTc (CO) 3-VIP analogues: preparation and evaluation as tumor imaging agent
Agostini et al. The [Tc (N)(PNP)] 2+ metal fragment labeled cholecystokinin‐8 (CCK8) peptide for CCK‐2 receptors imaging: in vitro and in vivo studies
Wendlinger et al. Novel radiohybrid PET-Tracers for SST
WO2025224092A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
Decristoforo et al. Technetium-99m labelling of RGD peptides targeting integrin receptors: Comparison of different conjugates of cRGDyK utilizing different technetium-99m cores
EP1913959A1 (en) Radioactive metal complexes comprising a tridentate complexing sequence

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080317

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080424

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080625

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090930

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091119

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120724

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131023

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees